This trial is evaluating whether Pharmacological Study will improve 3 primary outcomes, 5 secondary outcomes, and 7 other outcomes in patients with Therapy-Related Acute Myeloid Leukemia. Measurement will happen over the course of Up to 28 days.
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. Pharmacological Study is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Common treatments for leukemia include chemotherapy and targeted therapy, and chemotherapy has been shown to eradicate myeloid leukemia. Radiation therapy and targeted therapy are also effective, but only for limited-stage Hodgkin's disease." - Anonymous Online Contributor
"In the United States, the peak age of onset for acute myeloid leukemia is 38 years, and the age at peak incidence is 44 years; the average age of diagnosis is 62 years. The majority of people with acute myeloid leukemia are in the second decade of life when they are diagnosed with the disease, suggesting an age association with exposure to the environment and/or genetic factors. The median overall survival for first-time acute myeloid leukemia is only 3-4 months; the five-year survival rate is only 14%." - Anonymous Online Contributor
"The signs of leukemia include fever, weight loss, easy bruising, and pale or bluish skin. Bone pain, numbness or tingling also may be reported by patients with leukemias. In addition, diarrhea, constipation and easy bruising may be the first manifestation of a bone marrow disorder. If leukemia is suspected based on the symptoms, leukocyte counts and marrow aspirate and biopsy are strongly indicated." - Anonymous Online Contributor
"Leukemia is a blood disease that results when abnormal white blood cells grow and multiply at an abnormal rate. This disease usually follows an indolent but rapid course with symptoms ranging from only mild or absent, to severe, debilitating and sometimes fatal, symptoms. The disease will typically strike adults between the ages of 20-30 and will typically cause a bone marrow infection with leukemic cells. The disease is frequently treated with cytotoxic therapy with or without high-dose chemotherapy, a chemotherapeutic drug that selectively targets rapidly dividing cells." - Anonymous Online Contributor
"This patient was diagnosed with AML, a disease fatal in 3% of people, in our study. Our patient had not been treated with cytotoxic agents, and he did not survive. He died after a prolonged, severe and painful battle with leukemia, leaving his wife struggling with his disease and death while he was never aware of the severity of his disease or its ultimate outcome. His autopsy revealed several severe problems with most of the body, including sepsis, leukemia, and many severe infections. This case demonstrates the ultimate failure to live with the diagnosis of AML and to survive with therapy." - Anonymous Online Contributor
"The development of leukemia is likely the result of an error in the cellular formation in the bone marrow. This could be due to a blood disorder called imatinibs syndrome, or it may be due to genetics. When combined with a toxin, the likelihood that a child will develop leukemia can be increased. All of this is dependent on the development of the child and the amount and type of toxins he or she is exposed to.\n" - Anonymous Online Contributor
"The data presented is for three major drugs: etoposide, topotecan and mitoxantrone. Etoposide and topotecan are known to increase cell turnover in tumor cells. Mitoxantrone is a synthetic anthranilic acid antibiotic. It inhibits DNA replication by crosslinking the DNA of dividing cells and interfering with their mitosis. There has been recent development in these drugs use and they are being used more commonly. This is one of the newest drugs for hematological and malignancy purposes. Since its use in the past 15 years this has become a medication. The dosage of Topotecan has lately been changed; once a day was being used instead." - Anonymous Online Contributor
"This article aims to help people manage their leukemic condition for better care. The treatment depends on where the leukemic cells originate from, and how fast the leukemia gets worse, also, depends on the type of leukemia you are having. If the leukemia gets worse too fast, it may need to be treated quickly before the leukemia turns into acute leukemia (a form of chronic leukemia). If the leukemia is present for a while or doesn't rapidly get worse it is treated once per month for the first time, then once per month but the last treatment of the month should be given 4 weeks later and the next month and so on until it finishes." - Anonymous Online Contributor
"A meta-analysis of seven randomized controlled trials comparing the effectiveness of anakinra with placebo in the treatment of rheumatoid arthritis showed a significant increase in the likelihood of pain resolution with the anakinra treatment, which was not seen at either the early or mid to late end of follow up. Based on these data anakinra is advocated for patients with rheumatoid arthritis in order to improve their pain." - Anonymous Online Contributor
"The average age of people getting leukemia is 49.8, and the typical age of death is 69.5 in 2016. There have been 2 major studies on leukemia mortality – the USA and UK, and there is another study from Sweden which gives the exact numbers of deaths from leukemia in Sweden. The study shows that leukemia as a cause of death is slightly lower in Sweden than in the US and UK. The US has on average 9 deaths per month per 100,000 population while in Sweden it is about 5 and in UK it is 3. If we see this situation in statistics, I think it is easy to explain why leukemia is still a major problem in the United States and UK." - Anonymous Online Contributor
"Results from a recent paper did not demonstrate an improvement in patients with the addition of a systematic follow-up program compared with routine care or a routine follow-up programme." - Anonymous Online Contributor
"It was concluded that only a subset with chronic or chronic-intermittent leukemias has primary causation of leukemia. Patients with secondary causation for leukemia need prompt and appropriate therapy. If in the last five or ten years this cause is noticed then patients are typically diagnosed with secondary causation of leukemia. \n1. Chronic leukemias (also termed chronic myelogenous leukemia (CML)), e.g. Ph+CML\n2. Acute leukemias (also termed acute myelogenous leukemia (AML))\n3. Acquired leukemias (also termed AML)\n4." - Anonymous Online Contributor